Incorporated in 2018, NewWave Analytical Laboratory emerged from the Ontario Cancer Biomarker Network (now Indoc Research) where it served as the central proteomics core facility supporting researchers across Ontario and Canada for over 10 years
We are a certified mass spectrometry focused CRO, providing affordable and quality custom services to customers in early stage start-ups, biotech, pharma, health care organizations, hospitals, and the broader research community.
Our lab is located within St. Michael’s Hospital in downtown Toronto (Ontario, Canada) and is equipped with state-of-the-art equipment including hybrid triple quadrupole/linear ion trap mass spectrometers with analytical, micro and nano scale hyphenated HPLC capabilities.
We also have access to a full range of routine and specialized bioanalytical laboratory equipment, protocols and assays provided by the clinical biochemistry lab at St. Michael’s Hospital.
NewWave Analytical Laboratory was created with a vision to provide both custom and routine analytical services tailored to each of our customer’s individual needs. We have over 50 years of collective experience in designing and implementing mass spectrometry based analysis in both academic and commercial settings.
Dr. Jian Chen is the Managing Director and Lead Scientist at NewWave Analytical Laboratories. Previously, Dr. Chen was the Director of Proteomic Sciences at the Ontario Cancer Biomarker Network.
Dr. Alexander Romaschin is a certified Clinical Biochemist and Lead Scientist. Previously, Dr. Romaschin was the head of the Biochemistry Laboratory at St. Michael's Hospital.
Dr. Shane Climie is the Executive Director of Business Development. He has more than 20 years of R&D and business development experience in the life sciences and pharmaceutical industry. Dr. Climie is also the Principle at Popper and Co.
Dr. James Pan is the Senior Advisor for Scientific Strategy and Corporate Development. He brings over 20 years of experience for leading drug discovery and development in both industry and academia in protein, antibody & small molecule therapeutics and cancer biology. Previously, Dr. Pan was the Vice President of Product Development at The Centre for the Commercialization of Antibodies and Biologics (CCAB) in the University of Toronto.